RE:RE:RE:Medical Advisor Endocrinology United StatesI hope that is the way this works out as I would like to see TH give NASH a try. The rewards would be great if it was successful and I think there is enough data/Grinspoon research out there to suggest it has a decent chance of working in NASH. But they cannot raise money at a low price and expect shareholders to be happy. Now, the NASH trial will be a ball and chain on the stock to some degree until they get good data out of the first 400 patients. So, we need to be prepared to live with the market largely ignoring their NASH program until then. If the cancer program looks good, though, it will not be a huge ball and chain for the stock. It will just suck up capital and that may viewed as a folly by the market given the lack of a suitable phase II in NASH. I suspect it is not a folly but that is still how it will liely be viewed until there is good data to encourage investors to think of it otherwise.
Now, if they actually do have and/or get a decent parntership offer, that would crystallize the value of NASH for TH much faster in investor's eyes. I am not betting on that but I could be way off the mark with my current thinking/guessing.
Also, if they raised money prior to the cancer data being reported, that would not be a very good sign at all for cancer. I don't want to hear that they could not wait until that data was out because they needed to get going on NASH in order to not lose any competitive advantage they might have by getting the trials tartedd sooner..
Lee430 wrote: Maybe the answer is behind door #3 Cancer is looking great so they know the SP will be high enough to justify raising enough capitol to fund the trial at least till the futility results and then parntner for a much better deal.
palinc2000 wrote: Seems that they are putting more and more emphasis on Nash
My tea leave Reader tells me that this could be a sign that the Search for a Partner is not going as hoped and/or the Phase 1 in Oncology has not yet shown great success
This Tea Leave Reader has almost zero success rate in her predictions for THTX so take this with a grain of salt